The report covers a forecast and an analysis of the bile duct cancer drug market on a global and regional level. The study provides historical data for 2015, 2016, and 2017 along with a forecast from 2018 to 2024 based on revenue (USD million). The study includes drivers and restraints for the bile duct cancer drug market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the bile duct cancer drug market on a global level.
In order to give the users of this report a comprehensive view of the bile duct cancer drug market, we have included a competitive landscape and an analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.
The report provides company market share analysis to give a broader overview of the key market players. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launch, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the market on a global and regional basis.
The study provides a decisive view on the bile duct cancer drug market by segmenting the market based on type, application, and region. All the segments have been analyzed based on present and future trends and the market is estimated from 2018 to 2024.
By type, bile duct cancer drug market is segmented as 5-fluorouracil (5-FU), capecitabine, gemcitabine, oxaliplatin, cisplatin, and other. Based on application, bile duct cancer drug market has been segmented into hospitals, clinics, and others. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa with its further divided into major countries including the U.S., Germany, Italy, France, UK, China, Japan, India, and Brazil.
Some key players of the bile duct cancer drug market include Delcath Systems Inc., Accord Healthcare, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, Pfizer Inc., Eli Lilly and Company, Mylan N.V, Fresenius Kabi AG, Intercept Pharmaceuticals, Inc., and Celgene Corporation, among others.
This report segments the global bile duct cancer drug market into:
Global Bile Duct Cancer Drug Market: By Product
- 5-fluorouracil (5-FU)
- Gemcitabine (Gemcitabine Injection (the generic equivalent of Eli Lilly's, Gemzar®), available in 200mg/5.26mL, 1G/26.3mL and 2G/52.6mL; has an approximate market size of $25M, annually.)
Global Bile Duct Cancer Drug Market: By Application
Global Bile Duct Cancer Drug Market: By Region
- North America
- Asia Pacific
- Latin America
- Middle East and Africa